Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a well-
characterized tumour-suppressor gene that is lost or mutated in about half of metastatic …

Lipids, either endogenously synthesized or exogenous, have been linked to human cancer.
Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate …

Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene is often
altered in prostate cancer. To determine the prevalence and clinical significance of the …

Purpose: Analytically validated assays to interrogate biomarker status in clinical samples are
crucial for personalized medicine. PTEN is a tumor suppressor commonly inactivated in …

The classical action of androgen receptor (AR) is to regulate gene transcriptional processes
via AR nuclear translocation, response element binding and recruitment of, or crosstalk with …